Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech ChartsFundamental Analysis of AstraZenca Pharma India Ltd. - Growth / Value Index
ASTRAZEN - Valuation Highlights
Valuation Analysis
Book Value in last 3 years is trending up
Tsr Value Index - Very Poor Score of 13.89
Very Expensive - Price to Intrinsic Value of 3.93
Price to Earning Ratio is 103.55 and EV to EBITDA is 64.09 suggesting that it is very expensive
Price to Book Ratio of 27.24 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 101.47 | 185.91 | 125.39 % | ||
| Price to Book | 26.70 | 27.93 | 49.27 % | 25.51 | |
| Price to Sales | 9.36 | 12.54 | 21.92 % | ||
| Enterprise Value to EBITDA Multiple | 106.10 | 95.08 % |
ASTRAZEN - Profitability Highlights
Profitability Analysis
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 26.31%
Good Return On Capital Employed of 15.02
Tsr Profitability Index - Poor Score of 33.12
Very Low Dividend Yield of 0 %
EPS decline for last four quarters
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 26.31 | 15.02 | -33.77 % | 4.08 | |
| Return On Asset | 13.38 | 7.62 | -49.11 % | 2.02 | |
| Net Profit Margin | 9.23 | 6.74 | -45.91 % | 5.33 | |
| Operating Profit Margin | 13.03 | 12.38 | -4.69 % | 6.70 | |
| EBITDA Margin | 14.53 | 11.53 | -36.64 % | 8.41 |
Highlights
| Market Cap | 203862 M |
| Enterprise Value | 198563 M |
| Price/Book TTM | 26.70 |
| Outstanding Share | 25000.00 K |
| Float/ Outstanding Share | 18.41% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 10.92 |
| Peter Lynch Ratio | -0.279 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 19.04 |
| Sloan Ratio | 0.0129 |
| Peter Lynch Fair Value | 655.00 |
ASTRAZEN - Growth Highlights
Growth Analysis
Tremendous increasing trend in total sale last 3 year
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 27.79
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 2177.45 (Cr) | 32.48 % | 9.39 % |
| Gross Profit | 931.55 (Cr) | 69.44 % | 4.51 % |
| EBITDA | 316.33 (Cr) | 16.07 % | 32.37 % |
| Net Profit | 200.89 (Cr) | 28.34 % | 39.89 % |
| EPS | 80.36 | 28.33 % | NA |
ASTRAZEN - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 89.06
Altman Z Score of 19.37 suggests good Stability
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.0082 | 219.83 % | 0.0086 | |
| Cash Ratio | 0.763 | -46.10 % | ||
| Quick Ratio | 1.13 | -42.78 % | 0.871 | |
| Shareholders Equity | 50.74 | -23.16 % | ||
| Debt to EBITDA | 0.0317 | 312.34 % |
Historical Valuation Ratios of AstraZenca Pharma India Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of AstraZenca Pharma India Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of AstraZenca Pharma India Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of AstraZenca Pharma India Ltd.
Historical Solvency Ratios
Loading ...